OncoSec Medical (NASDAQ:ONCS) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCSGet Rating) in a research note published on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, BTIG Research lowered shares of OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.

OncoSec Medical Price Performance

Shares of ONCS opened at $3.73 on Monday. OncoSec Medical has a one year low of $3.35 and a one year high of $34.76. The company has a 50-day simple moving average of $10.55 and a two-hundred day simple moving average of $14.49. The firm has a market capitalization of $6.68 million, a PE ratio of -0.18 and a beta of 1.79.

Institutional Investors Weigh In On OncoSec Medical

A hedge fund recently raised its stake in OncoSec Medical stock. Bank of New York Mellon Corp raised its holdings in shares of OncoSec Medical Incorporated (NASDAQ:ONCSGet Rating) by 653.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 386,074 shares of the biotechnology company’s stock after acquiring an additional 334,849 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.98% of OncoSec Medical worth $444,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 13.22% of the company’s stock.

About OncoSec Medical

(Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.

Read More

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.